

**This is an abridged prospectus containing salient features of the Red Herring Prospectus dated March 4, 2016 ("RHP").
You are encouraged to read greater details available in the RHP.**

THE DOCUMENT CONSISTS OF FOUR PAGES OF APPLICATION FORM ALONG WITH INSTRUCTIONS AND SIX PAGES OF ABRIDGED PROSPECTUS. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.

You may obtain a physical copy of the ASBA form and the RHP from Stock Exchanges, Members of the Syndicate, Registered Brokers, Collecting Depository Participants, Registrar to the Offer, Registrar and Share Transfer Agents, Underwriters, Bankers to the Offer, Investors' Associations or Self Certified Syndicate Banks. You may also download the RHP from the websites of the Securities and Exchange Board of India ("SEBI"), the Book Running Lead Managers ("BRLMs") and where the Equity Shares are proposed to be listed ("Stock Exchanges") i.e. www.sebi.gov.in; www.nseindia.com; www.bseindia.com; www.investmentbank.kotak.com; www.edelweissfin.com; www.goldmansachs.com/worldwide/india/offerings.html; www.idfcapital.com; www.iifcap.com and www.yesbank.in. All capitalized terms used herein and not specifically defined shall have the same meanings as ascribed to them in the RHP.



HEALTHCARE GLOBAL ENTERPRISES LIMITED

Registered Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Contact Person: Sunu Manuel, Company Secretary and Compliance Officer; **Tel:** +91 80 4660 7700; **Fax:** +91 80 4660 7749
E-mail: investors@hcgoncology.com; **Website:** www.hcgel.com
Corporate Identity Number: U15200KA1998PLC023489

OUR PROMOTERS:

DR. BS AJAI KUMAR, DR. GANESH NAYAK, DR. BS RAMESH, DR. KS GOPINATH AND DR. M GOPICHAND

OFFER DETAILS, LISTING AND PROCEDURE

Initial Public Offer of up to 29,800,000 Equity Shares of Face Value of ₹10 each ("Equity Shares") of HealthCare Global Enterprises Limited ("Company" or "Issuer") for cash at a price of ₹[●] per Equity Share (including a share premium of ₹[●] per Equity Share) aggregating up to ₹[●] million ("Offer") comprising a fresh issue of up to 11,600,000 Equity Shares aggregating up to ₹[●] million ("Fresh Issue") and an offer for sale of up to 18,200,000 Equity Shares by the Selling Shareholders, including one of our Promoters, Dr. BS Ajai Kumar, aggregating up to ₹[●] Million ("Offer For Sale"). The Offer would constitute 35.03% of our post-Offer paid-up Equity Share Capital.

The face value of Equity Shares is ₹10 each. The Price Band and the minimum Bid Lot will be decided by Our Company and the Investor Selling Shareholders in consultation with the BRLMs and will be advertised in all editions of the English national newspaper, Business Standard, all editions of the Hindi national newspaper, Business Standard, and the Bengaluru, edition of the Kannada newspaper, Hosadigantha (Kannada being the Regional Language of Karnataka, where our Registered Office is located), each with wide circulation, at least five Working Days prior to the Bid/Offer Opening Date and shall be made available to the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") for the purpose of uploading on their websites.

Procedure:

If you wish to know about processes and procedures applicable to public issues, you may request for a copy of the General Information Document from the BRLMs or download it from the websites of BSE and NSE at www.bseindia.com and www.nseindia.com, and the BRLMs at www.investmentbank.kotak.com, www.edelweissfin.com, www.goldmansachs.com/worldwide/india/offerings.html, www.idfcapital.com, www.iifcap.com and www.yesbank.in

ELIGIBILITY FOR THE OFFER – Regulation 26(2) of SEBI ICDR Regulations, 2009

Whether the Company is compulsorily required to allot at least 75% of the Offer to Qualified Institutional Buyers - Yes

INDICATIVE TIMELINE

Bid Opening Date ¹	March 16, 2016	Initiation of Refunds (if any, for Anchor Investors)/ Unblocking of Funds from ASBA Accounts	On or about March 28, 2016
Bid Closing Date	March 18, 2016	Credit of Equity Shares to demat accounts of Allottees	On or about March 29, 2016
Finalization of Basis of Allotment with the Designated Stock Exchange	On or about March 23, 2016	Commencement of trading of Equity Shares on the Stock Exchanges	On or about March 30, 2016

¹ Our Company, in consultation with the Investor Selling Shareholders and the BRLMs, shall consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date.

GENERAL RISKS

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the RHP. Specific attention of the investors is invited to "Risk Factors" on page 17 of the RHP and on page 7 of this Abridged Prospectus.

PRICE INFORMATION OF BRLMs

Issue Name	Name of Merchant Banker	+/- % change in closing price, +/- % change in closing benchmark]- 30 th calendar days from listing	+/- % change in closing price, +/- % change in closing benchmark]- 90 th calendar days from listing	+/- % change in closing price, +/- % change in closing benchmark]- 180 th calendar days from listing
Dr. Lal PathLabs Limited	Kotak	+32.54%[-7.49%]	-	-
S H Kelkar and Company Limited	Kotak	+21.69%[-1.35%]	+20.78%[-10.58%]	-
Interglobe Aviation Limited	Kotak	+32.39%[-2.20%]	+7.76%[-5.09%]	-
Coffee Day Enterprises Limited	Kotak, Edelweiss, Yes	-21.42%[-1.19%]	-19.73%[-6.05%]	-
Sadbhav Infrastructure Project Limited	Kotak, Edelweiss	-2.28% [+3.55%]	-5.63%[-3.15%]	-
Power Mech Projects Limited	Kotak, IIFL	-9.36% [+0.98%]	-4.63%[+0.74%]	-10.65% [-7.15%]
Manpasand Beverages Limited	Kotak, IIFL	+23.20% [+2.83%]	+36.53% [-2.11%]	+58.34% [-6.45%]
Alkem Laboratories Limited	Edelweiss	30.34%; [-7.49%]	-	-
Prabhat Dairy Limited	Edelweiss	11.78% ; [3.57]	30.83%; [-1.79%]	-
Navkar Corporation Limited	Edelweiss	0.97%; [3.97%]	26.00%; [-0.68%]	-
Inox Wind Limited	Edelweiss, Yes	28.54%; [-6.68%]	42.42%; [-3.05%]	11.20%; [-7.51%]
Monte Carlo Fashions Limited	Edelweiss	-26.20%; [3.96%]	-23.57%; [5.60%]	-20.88%; [2.16%]
TeamLease Services Limited	IDFC	-	-	-
*Narayana Hrudayalaya Limited	IDFC	+27.28% [-4.20%]	-	-
PNC Infratech Limited	IDFC	+0.32% [+0.26%]	+14.66% [-6.36%]	+42.72% [-5.88%]
MEP Infrastructure Developers Limited	IDFC	-15.71% [+0.42%]	-8.57% [+5.51%]	-13.49% [-0.57%]
Sharda Cropchem Limited	IDFC, Edelweiss	+61.06% [-0.27%]	+63.56% [+3.82%]	+91.35% [+6.65%]
Repcos Home Finance Limited	IDFC	-0.64% [+3.96%]	+44.24% [+3.41%]	+41.19% [+2.26%]
Precision Camshafts Limited	IIFL	-	-	-
*Shemaroo Entertainment Limited	Yes	-6.5% [2.9%]	-6.5% [3.1%]	5.2% [5.3%]

Source: www.nseindia.com and Nifty 50 as the benchmark; *Source: www.bseindia.com and Sensex as the benchmark

Book Running Lead Managers

Kotak Mahindra Capital Company Limited Tel: +91 22 4336 0000; Fax: +91 22 6713 2447 E-mail: hcg.ipo@kotak.com Investor grievance email: kmccredressal@kotak.com Website: www.investmentbank.kotak.com Contact Person: Ganesh Rane	Edelweiss Financial Services Limited Tel: + 91 22 4009 4400, Fax: +91 22 4086 3610 Email: hcg.ipo@edelweissfin.com Investor grievance email: customerservice.mb@edelweissfin.com Website: www.edelweissfin.com Contact Person: Siddharth Shah/Vivek Kumar
Goldman Sachs (India) Securities Private Limited Tel: +91 22 6616 9000, Fax: +91 22 6616 9090 Email: gs-hcg-ipo@gs.com Investor grievance email: india-client-support@gs.com Website: http://www.goldmansachs.com/worldwide/india/offerings.html Contact Person: Dipak Daga	IDFC Securities Limited Tel: +91 22 6622 2600, Fax: +91 22 6622 2501 Email: hcg.ipo@idfc.com Investor grievance email: investorgrievance@idfc.com Website: www.idfccapital.com, Contact Person: Gaurav Goyal
IIFL Holdings Limited Tel: +91 22 4646 4600, Fax: +91 22 2493 1073 Email: hcg.ipo@iiflcap.com Investor grievance email: ig.ib@iiflcap.com Website: www.iiflcap.com Contact Person: Pinak Bhattacharyya/Vishal Bangard	Yes Bank Limited Tel: +91 22 3366 9000, Fax: +91 22 2421 4508 Email: dlhcgipo@yesbank.in Investor grievance email: merchantbanking@yesbank.in Website: www.yesbank.in Contact Person: Dhruvin Mehta

Registrar to the Offer :

Karvy Computershare Private Limited, Karvy Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad 500 032; Tel: +91 40 6716 2222; Fax: +91 40 2343 1551, E-mail: einward.ris@karvy.com, Investor grievance email: hcgglobal.ipo@karvy.com, Website: www.karisma.karvy.com, Contact Person: Rakesh Santhalia, SEBI Registration No.: INR000000221

Syndicate Members

Kotak Securities Limited, Edelweiss Securities Limited, Sharekhan Limited and India Infoline Limited.

International Legal Counsel to BRLMs	Clifford Chance Pte. Ltd.	Indian Legal Counsel to Company	Cyril Amarchand Mangaldas
Indian Legal Counsel to BRLMs	AZB and Partners	Auditors to Company	Deloitte Haskins & Sells

Self Certified Syndicate Banks: The list of banks that have been notified by SEBI to act as the SCSBs for the ASBA process is provided on the website of SEBI at <http://www.sebi.gov.in/sebiweb/home/list/5/33/0/0/Recognised-Intermediaries>. For list of branches of the SCSBs named by the respective SCSBs to receive the ASBA Forms from the Designated Intermediaries, please refer to the above-mentioned link.

Registered Brokers: The list of the Registered Brokers, including details such as postal address, telephone number and e-mail address, is provided on the websites of the Stock Exchanges at http://www.bseindia.com/Markets/PublicIssues/brokercentres_new.aspx?expandable=3 and http://www.nseindia.com/products/content/equities/ipos/ipo_mem_terminal.htm, respectively, as updated from time to time.

Registrar and Share Transfer Agents (“RTAs”) and Collecting Depository Participants (“CDPs”): The list of the RTAs eligible to accept ASBA Forms at the Designated RTA Locations and the list of the CDPs eligible to accept ASBA Forms at the Designated CDP Locations, including details such as name and contact details, is provided on the websites of Stock Exchanges at <http://www.bseindia.com/Static/Markets/PublicIssues/RtaDp.aspx?expandable=6> and http://www.nseindia.com/products/content/equities/ipos/asba_procedures.htm, as updated from time to time.

PROMOTERS OF OUR COMPANY

Dr. BS Ajai Kumar: aged 64 years, is the Chairman and Chief Executive Officer of our Company. He holds a bachelor’s degree in Medicine and Surgery from St. John’s Medical College, Bengaluru, India. He completed his residency in Oncology from the University of Virginia Hospital, Charlottesville and his residency in Radiotherapy from the University of Texas System Cancer Centre, MD Anderson Hospital and Tumour Institute, Texas, United States of America. He has been awarded the Ernst and Young Entrepreneur of the Year Award for the start-up category in healthcare and the BC Roy Award by the Indian Science Monitor.

Dr. KS Gopinath: aged 63 years. He holds a bachelor’s degree in Medicine and Surgery from JJM Medical College, Davangere, Karnataka, a master’s degree in General Surgery from the Mumbai University, Maharashtra. He is an honorary fellow of the Royal College of Surgeons, Edinburgh, United Kingdom, and has completed his fellowship in General Surgery and Oncology at the International College of Surgeons. He has also been awarded a fellowship at the Memorial Sloan Kettering Cancer Centre. He has been awarded the Padma Shree Award by the President of India in 2010.

Dr. Ganesh Nayak: aged 73 years. He holds a bachelor’s degree in Medicine and Surgery and a master’s degree in Surgery from the University of Mysore. He is also a Fellow of the Indian College of Cardiology and a Fellow of the International College of Surgery. He has been working at Agadi Hospital and Research Centre and PD Hinduja Sindhi Hospital since 1983 as a consultant cardiothoracic and vascular surgeon and at Bhagwan Mahaveer Jain Hospital since 1990 as a consultant cardiothoracic surgeon.

Dr. M Gopichand: aged 53 years. He holds a bachelor’s degree in Medicine and Surgery from the University of Mysore, a master’s degree in General Surgery from the Bangalore University, a diploma in General Surgery from the National Board of Examinations, New Delhi and an M Ch. from Bengaluru. He presently also practices at the City Cancer Centre.

Dr. BS Ramesh: aged 64 years. He has completed his MBBS from Bangalore University, he holds a degree of Doctor of Medicine (Radio Therapy), a post graduate diploma in Radio Diagnosis from Bangalore University and a Post Graduate Diploma in Medical Law And Ethics from the National Law School of India University, Bengaluru. He is experienced in the field of Radiation Oncology.

None of our Group Companies are listed on any Stock Exchange.

BUSINESS MODEL / BUSINESS OVERVIEW AND STRATEGY

We are a provider of speciality healthcare in India focused on cancer and fertility. Under the “HCG” brand, we operate the largest cancer care network in India in terms of the total number of private cancer treatment centres licensed by the AERB as of May 31, 2015. (Source: Government of India, Atomic Energy Regulatory Board). Under the “Milann” brand, we operate our fertility centres. As of December 31, 2015, our HCG network consisted of 14 comprehensive cancer centres, including our centre of excellence in Bengaluru, three freestanding diagnostic centres and one day care chemotherapy centre across India. Each of our comprehensive cancer centres offers, at a single location, comprehensive cancer diagnosis and treatment services (including radiation, medical oncology and surgical treatments). Our freestanding diagnostic centres and our day care chemotherapy centre offer diagnosis and medical oncology services, respectively.

Our Strengths: • Largest provider of cancer care in India with a proven track record; • High quality cancer care provided at a competitive price; • Entry into high potential fertility business; • Strong management team with successful track record; • Highly skilled specialist physicians; and • Our business model and partnership arrangements.

Our Strategies: • Expand the reach of our cancer care network in India • Strengthen our HCG brand to reach more cancer patients • Expand our cancer care network to Africa • Upgrade and strengthen our information technology infrastructure • Expand our Milann network of fertility centres across India and build our Milann brand.

BOARD OF DIRECTORS

S. No.	Name	Designation	Experience including current/ past position held in other firms
1.	Dr. BS Ajai Kumar	Chairman and Chief Executive Officer	For details, refer to page 5 of this Abridged Prospectus.
2.	Gangadhara Ganapati	Non-Executive Director	He has worked as managing director of Adamas India Pharmaceuticals Private Limited. He founded Triesta Sciences, Inc. and served as its chief executive officer from 2002 until 2006. He served in the Tata Administrative Service from 1990 to 1994.
3.	Prakash Parthasarathy	Non-Executive, Nominee Director	He serves as the chief investment officer of Premiji Invest and its affiliates and is a director on the boards of the NSE and FabIndia Overseas Private Limited.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

4	Dr. Jennifer Gek Choo Lee	Non-Executive, Nominee Director	She is chairperson of Agency of Integrated Care Pte Limited. She is a corporate advisor with Temasek International Advisors Pte. Ltd. She has served as chief executive officer of KK Women's and Children's Hospital, Singapore. She was a nominated member of the Singapore Parliament between 1999 and 2004.
5	Rajesh Singhal	Non-Executive, Nominee Director	He serves on the boards of AIM Education Private Limited, Capricorn Food Products India Limited, IBOF Investment Management Private Limited, IMS Learning Resources Private Limited and Resonance Eduventures Private Limited.
6	Sudhakar Rao	Non-Executive, Independent Director	He is a retired Indian Administrative Service Officer and he has held several posts in the government including the post of the chief secretary to the Government of Karnataka. He has previously been a director on the boards of Indian Oil Corporation Limited and Binani Industries Limited.
7	Shanker Annaswamy	Non-Executive, Independent Director	He has been the managing director of IBM India Private Limited, and the regional general manager of IBM in India/South Asia. He has been the president and chief executive officer of GE Medical Systems, South Asia.
8	Sampath Thattai Ramesh	Non-Executive, Independent Director	He is a retired civil servant who served in the Karnataka Police Department and the Government of India. He was the former Director General and Inspector General of Police, Karnataka.
9	Suresh Chandra Senapaty	Non-Executive, Independent Director	He has held several positions at Wipro Limited including that of the chief financial officer. He has also been a director of Wipro Corporation, Wipro GE Healthcare and Wipro Enterprises Limited.
10	Bhushani Kumar	Non-Executive, Independent Director	She is presently the Secretary at Women's Peace League, Basavanagudi, Bengaluru.

OBJECTS OF THE OFFER

The Offer comprises of Fresh Issue and the Offer for Sale.

Fresh Issue: The fund requirements for each of the Objects of the Offer are stated as below:

(₹ in million)

Particulars	Total estimated costs	Amount to be funded from the Net Proceeds ⁽³⁾	Estimated Utilisation of Net Proceeds		
			Fiscal 2017	Fiscal 2018	Fiscal 2019
Purchase of medical equipment	422.07	422.07	422.07	-	-
Investment in IT software, services and hardware ⁽¹⁾	416.09	301.94	53.98	161.14	86.82
Pre-payment of debt	1,470.48	1,470.48	1,470.48	-	-
General corporate purposes ⁽²⁾	[●]	[●]	[●]	[●]	[●]
Total	[●]	[●]	[●]	[●]	[●]

(1) The balance estimated costs for the purpose of financing this Object shall be met from our internal accruals

(2) To be finalized upon determination of the Offer Price

(3) Based on certificate dated January 15, 2016 from HRA & Co., Chartered Accountants, as of, January 15, 2016 no funds have been deployed towards the aforementioned Objects.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues/ rights issues, if any, of the Company in the preceding 10 years - Not Applicable

We are not required to appoint a monitoring agency since the Fresh Issue size is not in excess of ₹5,000 million.

Offer for Sale: Upto 18,200,000 Equity Shares proposed to be sold by Selling Shareholders, as follows:

Selling Shareholder	Number of Equity Shares offered in the Offer for Sale	Selling Shareholder	Number of Equity Shares offered in the Offer for Sale
AOPL	579,948	Gangadhara Ganapati	600,000
Dr. BS Ajai Kumar	183,260	MAT of which Shachindra Nath is the trustee	334,327
Dr. G Kilara	30,000	MPEF through its scheme India Build-Out Fund-I, of which IL&FS Trust Company Limited is a Trustee	9,520,067
Dr. K Harish jointly with Shubha Harish	5,594	PIOF	3,450,000
Dr. Nalini Kilara	5,000	Rajesh Ramaiah	15,000
Shubha Harish jointly with Dr. K Harish	11,804	V-Sciences	3,450,000
Ganga Ramaiah	15,000		

Shareholding Pattern of our Company as on the date of the RHP:

Sr. No.	Particulars	Pre-Offer number of shares	Pre-Offer Shareholding (%)
1.	Promoters and Promoter Group	21,123,422	28.75
2.	Public	52,352,564	71.25
	Total	73,475,986	100.00

RESTATED AUDITED FINANCIALS

(₹ in million, except per share data)

Unconsolidated	As at and for the nine months ended November 30, 2015*	As at and for the six months ended September 30,		As at and for the year ended March 31,				
		2015*	2014*	2015	2014	2013	2012	2011
Total income from operations (net)	3,038.64	2,272.97	2,057.76	4,201.50	3,490.98	2,914.18	2,018.34	1,590.71
Net Profit/Loss before tax and extraordinary items	(34.97)	(27.31)	(41.74)	(33.58)	(361.13)	(65.78)	(35.51)	29.21
Net Profit/Loss after tax and extraordinary items	(61.49)	(45.27)	(28.21)	(23.66)	(394.98)	(71.58)	(40.02)	34.40
Equity Share Capital	734.76	729.60	688.25	699.84	682.45	668.90	592.72	533.04
Reserves and Surplus	2,108.11	2,072.63	1,909.60	2,008.33	1,919.18	2,169.00	1,486.07	1,073.68
Net Worth	2,842.87	2,802.23	2,606.32	2,716.64	2,607.43	2,843.70	2,078.79	1,680.66
Basic earnings per share (₹)	(0.85)	(0.63)	(0.40)	(0.34)	(5.75)	(1.19)	(0.72)	0.65
Diluted earnings per share (₹)	(0.85)	(0.63)	(0.40)	(0.34)	(5.75)	(1.19)	(0.72)	0.64
Return on Net Worth (%)	(2)%	(2)%	(1.08)%	(0.87)%	(15.15)%	(2.52)%	(1.93)%	2.05%
Net asset value per share (₹)	36.88	36.35	33.81	35.24	35.85	40.35	33.38	30.45

*Not Annualised

(₹ in million, except per share data)

Consolidated	As at and for the nine months ended November 30, 2015*	As at and for the six months ended September 30,		As at and for the year ended March 31,				
		2015*	2014*	2015	2014	2013	2012	2011
Total income from operations (net)	3,788.87	2,854.29	2,554.45	5,193.75	4,513.34	3,383.05	2,665.83	2,148.18
Net Profit/Loss before tax and extraordinary items	47.20	41.95	19.36	70.02	(261.89)	(101.45)	(28.78)	80.23
Net Profit/Loss after tax and extraordinary items	(37.11)	(7.49)	(11.17)	5.46	(355.53)	(105.14)	(33.31)	62.99
Equity Share Capital	734.76	729.60	688.25	699.84	682.45	668.90	592.72	533.04
Reserves and Surplus	2,210.59	2,188.19	1,975.37	2,086.61	1,949.44	2,159.30	1,519.63	1,103.49
Net Worth	2,945.35	2,917.79	2,672.09	2,794.92	2,637.69	2,834.00	2,112.35	1,710.47
Basic earnings per share (₹)	(0.51)	(0.10)	(0.16)	0.08	(5.18)	(1.74)	(0.60)	1.19
Diluted earnings per share (₹)	(0.51)	(0.10)	(0.16)	0.07	(5.18)	(1.74)	(0.60)	1.17
Return on Net Worth (%)	(1.26)%	(0.26)%	(0.42)%	(0.20)%	(13.48)%	(3.71)%	(1.58)%	3.68%
Net asset value per share (₹)	38.21	37.85	34.66	36.26	36.26	40.21	33.92	30.99

*Not Annualised

INTERNAL RISK FACTORS

Below are the top 5 Risk Factors as per the RHP:

1. We and two of our Subsidiaries have reported net losses in the recent fiscal periods and may be unable to achieve or sustain profitability in the future, which may materially and adversely impact our business and prospects.
2. There have been incidents of fraud committed by employees of one of our former subsidiaries as well as by senior managers at our cancer centres in the past. If such incidents of fraud were to recur, our business, reputation and results of operations could be materially and adversely affected.
3. Our results of operations are likely to vary from period to period and be unpredictable, which could cause the market price of the Equity Shares to decline.
4. The success of our business is dependent on our ability to maintain and expand our HCG network and our Milann network. If we are unable to successfully maintain or expand our HCG network and our Milann network or if any of our existing centres or hospitals are closed down, our business, financial condition and cash flows could be materially and adversely affected.
5. We cannot assure you that we will be able to successfully execute our growth strategies, which could affect our business, prospects and results of operations.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. Total number of outstanding litigations against the company and amount involved: There are 30 outstanding litigations filed against us and the approximate amount involved, wherever quantifiable, is ₹ 62.95 million.

B. Brief details of the top 5 material outstanding litigations against the Company and the amount involved:

S. No.	Particulars	Litigation filed by	Current Status	Amount Involved (in ₹ million)
1	Notice under Section 156 of IT Act for Assessment years 2011 -12 and 2012 -13 for tax deducted at source for fixed pay consultants.	Assistant Commissioner of Income Tax, Bangalore	Our Company has paid 50% of the demanded amount and have replied to similar notices for the FY 2012-13 and 2013-14	35.82
2	The husband of one of our patients has filed a consumer complaint against our Hospital and two other hospitals before the Karnataka State consumer Disputes Redressal Forum alleging medical negligence on the part of our Hospital.	Mr. Venkatesh	Matter is currently pending.	9.99
3	Notice from Commissioner of Central Excise demanding a sum for the manufacture of 'FDG-18' which is an excisable good and for confiscation of the same.	Commissioner of Central Excise, Bengaluru and Chennai Excise Commiserate.	Our Company has responded to notices issued for the years upto FY 2013-14 and are yet to respond to notices for FY 2014-15.	6.80
4	Assessment Order for the return of income for assessment year 2011-2012.	Deputy Commissioner of Income Tax, Bangalore	Matter is currently pending.	3.73
5	Assessment order of value added tax.	Commercial Tax Department	Matter is currently pending.	2.00

C. There are no disciplinary actions taken by SEBI or the Stock Exchanges against the Promoters/ Group Companies in the last five financial years.

D. Brief details of Outstanding criminal proceedings against our Promoters:

1. A complaint has been filed before the Station House Officer, Lakshmiapuram Police Station, Mysuru, by the head constable attached to the police station alleging that our Promoter, Dr. BS Ajai Kumar and another person used criminal force and deterred the constable from discharging his duties during a public event at the Maharaja College grounds, Mysuru. A charge sheet was prepared charging our Promoter with offences punishable under Section 353 and Section 506 read with Section 34 of the Indian Penal Code, 1860. The jurisdictional magistrate had taken cognizance of the offences in the charge sheet by his order dated December 14, 2007. The High Court of Karnataka by its order dated August 30, 2013 has quashed the order of the magistrate on the grounds that the magistrate had not applied his judicious mind and has directed the magistrate to re-do the whole process from the stage of taking cognizance. The matter is currently pending.
2. A complaint has been filed before the Station House Officer, Cubbon Park Police Station, Bengaluru by a patient treated by our Promoter, Dr. Ganesh Nayak accusing Dr. Ganesh Nayak of improper conduct during a medical examination. A case has been registered against our Promoter for offences punishable under Sections 376(2)(e) and 376(2)(k) of the Indian Penal Code, 1860. By its order dated June 12, 2015 the Additional City Civil and Sessions Judge, Bengaluru has granted our Promoter anticipatory bail in the matter. The matter is currently pending.

ANY OTHER IMPORTANT INFORMATION AS PER BRLM / ISSUER COMPANY - NIL

DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of Companies Act, and the guidelines issued by the Government or the regulations, rules or guidelines issued by SEBI, established under section 3 of the SEBI Act, as the case may be, have been complied with and no statement made in the Red Herring Prospectus is contrary to the provisions of the Companies Act, the SCRA, the SEBI Act or rules or regulations made there under or guidelines issued, as the case may be. We further certify that all the statements in the RHP are true and correct.

DECLARATION BY THE SELLING SHAREHOLDERS

Each of the Selling Shareholders, hereby certifies that all statements and undertakings made by it in the RHP about it or in relation to itself and the Equity Shares being sold by it in the Offer for Sale are true and correct, provided however, that such Selling Shareholder assumes no responsibility for any of the statements made by the Company or any expert or any other person(s) in the RHP.

THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.

THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.